

Zydelig - (100 mg and 150 mg ; Tablets)

| | | | |
|------------------------------|--|-----------------------------|---------------------|
| Generic Name | Idelalisib | Innovator | Gilead |
| Dosage | 100 mg and 150 mg ; Tablets | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | Less Than 5 | Tentative Approvals | None |
| Final Approvals | Less Than 5 | Generic Launches | None |
| Indication | Zydelig is a kinase inhibitor indicated for the treatment of patients with: • Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities. • Relapsed follicular B-cell non-Hodgkin Lymphoma (FL) in patients who have received at least two prior systemic therapies. • Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.